1. Home
  2. PRQR vs SSBK Comparison

PRQR vs SSBK Comparison

Compare PRQR & SSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRQR
  • SSBK
  • Stock Information
  • Founded
  • PRQR 2012
  • SSBK 2007
  • Country
  • PRQR Netherlands
  • SSBK United States
  • Employees
  • PRQR N/A
  • SSBK N/A
  • Industry
  • PRQR Biotechnology: Pharmaceutical Preparations
  • SSBK Commercial Banks
  • Sector
  • PRQR Health Care
  • SSBK Finance
  • Exchange
  • PRQR Nasdaq
  • SSBK Nasdaq
  • Market Cap
  • PRQR 179.1M
  • SSBK N/A
  • IPO Year
  • PRQR 2014
  • SSBK 2021
  • Fundamental
  • Price
  • PRQR $2.13
  • SSBK $36.37
  • Analyst Decision
  • PRQR Strong Buy
  • SSBK Buy
  • Analyst Count
  • PRQR 8
  • SSBK 1
  • Target Price
  • PRQR $8.88
  • SSBK $36.00
  • AVG Volume (30 Days)
  • PRQR 362.3K
  • SSBK 34.0K
  • Earning Date
  • PRQR 08-07-2025
  • SSBK 07-21-2025
  • Dividend Yield
  • PRQR N/A
  • SSBK 0.99%
  • EPS Growth
  • PRQR N/A
  • SSBK 6.02
  • EPS
  • PRQR N/A
  • SSBK 3.80
  • Revenue
  • PRQR $21,212,711.00
  • SSBK $99,026,000.00
  • Revenue This Year
  • PRQR N/A
  • SSBK $19.18
  • Revenue Next Year
  • PRQR N/A
  • SSBK $7.05
  • P/E Ratio
  • PRQR N/A
  • SSBK $9.57
  • Revenue Growth
  • PRQR 85.91
  • SSBK 18.43
  • 52 Week Low
  • PRQR $1.07
  • SSBK $25.92
  • 52 Week High
  • PRQR $4.62
  • SSBK $39.16
  • Technical
  • Relative Strength Index (RSI)
  • PRQR 64.73
  • SSBK 61.75
  • Support Level
  • PRQR $1.89
  • SSBK $35.46
  • Resistance Level
  • PRQR $2.54
  • SSBK $36.80
  • Average True Range (ATR)
  • PRQR 0.14
  • SSBK 0.64
  • MACD
  • PRQR 0.01
  • SSBK 0.18
  • Stochastic Oscillator
  • PRQR 43.06
  • SSBK 85.17

About PRQR ProQR Therapeutics N.V.

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.

Share on Social Networks: